Results 11 to 20 of about 50,773 (265)

Janus kinase inhibitors for the therapy of atopic dermatitis [PDF]

Allergologie select, 2021
The JAK-STAT pathway is involved in the signaling of multiple cytokines driving cutaneous inflammation in atopic dermatitis (AD). Janus kinase (JAK) inhibitors target individual receptor-associated kinases, thereby preventing the mediation of inflammatory signals.
Traidl, Stephan, Freimooser, Sina, Werfel, Thomas   +2 more
openaire   +2 more sources

Acute retinal necrosis during the systemic use of Janus kinase inhibitor [PDF]

International Journal of Retina and Vitreous
Daisuke Watanabe, Kenichi Namba, Keitaro Hase, Kayo Suzuki, Yo Ogino, Michiyuki Saito, Daiju Iwata, Kazuomi Mizuuchi, Miki Hiraoka, Mao Narita, Nobuyoshi Kitaichi, Norihiko Kitaya, Susumu Ishida   +12 more
doaj   +2 more sources

Janus kinase inhibitors in autoimmune diseases [PDF]

Annals of the Rheumatic Diseases, 2013
Biological therapies directed at proinflammatory cytokines have irrevocably changed the landscape of treatment of rheumatoid arthritis (RA) and other autoimmune diseases. With the advances in our knowledge in cytokine signalling, the question emerges whether targeting intracellular signalling might also be a safe and efficacious strategy. Janus kinases
John J, O'Shea, Apostolos, Kontzias, Kunihiro, Yamaoka, Yoshiya, Tanaka, Arian, Laurence   +4 more
openaire   +2 more sources

Effectiveness of upadacitinib in Japanese patients with prurigo‐type atopic dermatitis: Four cases report

Journal of Cutaneous Immunology and Allergy, 2023
We present four Japanese patients with prurigo‐type AD who received upadacitinib. Rapid improvement of skin lesions and itchiness was seen in all patients. Janus kinase inhibitor is effective for prurigo‐type AD by strongly suppressing itching.
Keiji Kosaka, Akihiko Uchiyama, Mai Ishikawa, Sei‐ichiro Motegi   +3 more
doaj   +1 more source

In silico method potential therapeutic use of Janus Kinase inhibitors as severe acute respiratory syndrome coronavirus 2 main protease inhibitors

Journal of the Scientific Society, 2023
Background: Coronavirus disease 2019 (COVID-19), it is an infectious respiratory disease caused by SARS corona virus 2 (SARS CoV-2). There are several reports of using JAK (Janus kinase)-inhibitors in persons with COVID-19 and the use of these decreased ...
Shankar Gharge, Sushmita I Hiremath, Akshata S Menasinakai, Mahesh S Palled   +3 more
doaj   +1 more source

A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: A case report

SAGE Open Medical Case Reports, 2023
Bullous pemphigoid is an acquired autoimmune subepidermal blistering disease that can arise following exposure to systemic medication, referred to as drug-induced bullous pemphigoid.
Louise M Gresham, Mark G Kirchhof
doaj   +1 more source

Development of an enzyme-coupled activity assay for Janus kinase 2 inhibitor screening

SLAS Discovery, 2023
JAK2 transmits signals of several important cytokines, such as growth hormone and erythropoietin. The interest toward the therapeutic targeting of JAK2 was boosted in 2005, when the somatic JAK2 V617F mutation, responsible for the majority of ...
Angelika Pölläniemi, Anniina Virtanen, Olli Silvennoinen, Teemu Haikarainen   +3 more
doaj   +1 more source

Malignant progression of liver cancer progenitors requires lysine acetyltransferase 7–acetylated and cytoplasm‐translocated G protein GαS

Hepatology, EarlyView., 2022
KAT7‐acetylated and cytoplasm‐translocated G‐protein GαS enhances IL‐6 effect and drives HCC progenitor cell progression. Abstract Background and Aims Hepatocarcinogenesis goes through HCC progenitor cells (HcPCs) to fully established HCC, and the mechanisms driving the development of HcPCs are still largely unknown.
Ye Zhou, Kaiwei Jia, Suyuan Wang, Zhenyang Li, Yunhui Li, Shan Lu, Yingyun Yang, Liyuan Zhang, Mu Wang, Yue Dong, Luxin Zhang, Wannian Zhang, Nan Li, Yizhi Yu, Xuetao Cao, Jin Hou   +15 more
wiley   +1 more source

Janus kinase inhibitors: jackpot or potluck?

Oncology Reviews, 2012
The reports of a unique mutation in the Janus kinase-2 gene (JAK2) in polycythemia vera by several independent groups in 2005 quickly spurred the development of the Janus kinase inhibitors.
Pavithran Keechilat, Shripad Brahmanand Pande   +1 more
doaj   +1 more source

IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH

Hepatology, EarlyView., 2022
IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases Abstract Background and Aims Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood.
Jun Xu, Ya Wang, Mina Khoshdeli, Matt Peach, Jen‐Chieh Chuang, Julie Lin, Wen‐Wei Tsai, Sangeetha Mahadevan, Wesley Minto, Lauri Diehl, Ruchi Gupta, Michael Trauner, Keyur Patel, Mazen Noureddin, Kris V. Kowdley, Aliya Gulamhusein, Christopher L. Bowlus, Ryan S. Huss, Robert P. Myers, Chuhan Chung, Andrew N. Billin   +20 more
wiley   +1 more source